Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments.
| Business Activity | PASS |
| Debt Ratio (0.23%) | PASS |
| Cash Ratio (0.05%) | PASS |
| Receivables Ratio (0.08%) | PASS |
| Revenue Ratio (0.01%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | 2.00 | Pending | -- |
| 2026-03-05 | 1.94 | 1.88 | -3.1% |
| 2025-11-13 | 2.20 | 2.32 | +5.6% |
| 2025-08-07 | 2.14 | 2.02 | -5.5% |
| 2025-05-15 | 2.16 | 2.12 | -1.9% |
| 2025-03-06 | 2.19 | 2.07 | -5.4% |
| 2024-11-13 | 2.27 | 2.30 | +1.3% |
| 2024-07-31 | 1.91 | 2.20 | +15.4% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5.1B | $659.0M | $1.5B | $3.1B | $943.0M | 1.52 |
| 2025-12-31 | $5.2B | $319.0M | $1.4B | $3.0B | $547.0M | — |
| 2025-09-30 | $5.3B | $902.0M | $1.7B | $3.2B | $1.2B | 2.07 |
| 2025-06-30 | $5.3B | $652.0M | $1.4B | $3.0B | $892.0M | 1.50 |
| 2025-03-31 | $5.3B | $735.0M | $1.5B | $3.1B | $1.0B | 1.69 |
| 2024-09-30 | — | — | — | — | — | 1.86 |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Generali Investments Cee, Investicni Spolecnost, A.s. | 6.2K | $801.9K | — |
| Reik & Co., Llc | 4.0K | $514.4K | — |
| Pacer Advisors, Inc. | 2.8K | $357.8K | — |
| Gamma Investing LLC | 34.0 | $4.4K | — |
$64.1B
1.88
0.784
15
$21.0B
$12.0B
-10.1%
1.9%
1.81
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $2.00 | Pending | — |
| 2026-03-05 | $1.94 | $1.88 | -3.1% |
| 2025-11-13 | $2.20 | $2.32 | +5.6% |
| 2025-08-07 | $2.14 | $2.02 | -5.5% |
| 2025-05-15 | $2.16 | $2.12 | -1.9% |
| 2025-03-06 | $2.19 | $2.07 | -5.4% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($143.33, 15 analysts) | |||
| 10 | $1,128.50 | +$304.80 (27%) | 1.8R |
| 50 | $5,642.50 | +$1,524.00 (27%) | 1.8R |
| 100 | $11,285.00 | +$3,048.00 (27%) | 1.8R |
| To Fair Value ($40.57) | |||
| 10 | $1,128.50 | +$-722.80 (-64%) | -4.3R |
| 50 | $5,642.50 | +$-3,614.00 (-64%) | -4.3R |
| 100 | $11,285.00 | +$-7,228.00 (-64%) | -4.3R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| MKKGY | 0.762 |
| LWDB.L | 0.446 |
| BRGE.L | 0.443 |
| FEV.L | 0.442 |
| MUT.L | 0.442 |
| Ticker | Correlation |
|---|---|
| BAES.L | -0.282 |
| LPTVQ | -0.151 |
| KR | -0.149 |
| ORDS.AB | -0.139 |
| USO | -0.138 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.